logo
Share SHARE
FONT-SIZE Plus   Neg

Actelion Q1 Profit Falls As Market Place Remains Challenging - Update

Swiss pharmaceutical firm Actelion Ltd. (ALIOF.PK) on Thursday reported lower profit for the first quarter, amid a decline in revenue and a strong Swiss franc. In addition, the company reaffirmed its 2012 flat core earnings forecast and upgraded product sales guidance to low single digit decrease.

GAAP net income fell to 45.06 million francs ($49.15 million) or 0.38 francs per share from 146.29 million francs or 1.20 francs per share in the prior year.

Core earnings, which are product sales minus cash operating expenses and other items, fell to 107.6 million francs from 127.9 million francs. Core earnings per share declined 31 percent to 0.66 francs.

Net revenue dropped to 417.47 million francs from 528.23 million francs a year earlier. Product sales slid 4 percent in local currencies to 415.8 million francs.

Thirty-seven percent of sales came from the U.S., 41 percent from Europe, 11 pecrent from Japan and another 11 percent from the rest of the world. In local currencies, pulmonary hypertension drug Tracleer's sales dropped 6 percent to 363.7 million francs.

Jean-Paul Clozel, CEO of Actelion, said the market place remains challenging as expected, due mainly to changes in the competitive landscape in the U.S. and strong pricing pressures in certain markets.

Actelion had previously expected product sales in local currencies in 2012 to decrease in the low-to mid-single digit range. In the first quarter, while overall pricing pressure remained high, the US pricing environment improved slightly.

The company's CFO Andrew Oakley said, "Unforeseen events excluded, Actelion can now provide an improved product sales forecast. The decrease in local currencies is now expected to be in the low-single digit range. Actelion remains on track to meet its previously issued guidance of flat 2012 core earnings."

Further, the company said it expects results for its second-generation endothelin receptor antagonist macitentan in morbidity/mortality PAH study in the next few weeks.

The stock closed lower by 3.01 percent at 32.21 francs on 531,269 shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Volkswagen plans to invest about 22.8 billion euros in its core brand from 2018 to 2022, with main focus on e-mobility and modularization. In a statement on Saturday, the German automaker announced that the investments, as part of the brand's Transform 2025+ strategy, will significantly boost the brand's largest product and technology offensive. Health IQ Insurance Services, a startup focused on providing life insurance for health-conscious individuals, said it has secured $34.6 million in Series C funding, led by Andreessen Horowitz. To date, the company has raised a total of $81 million in funding mostly from its existing investors. General Motors Co. is recalling nearly 49,000 trucks worldwide to fix a fuel tank issue that can increase the risk of a fire. The recall covers Chevrolet Silverado 3500 and GMC Sierra 3500 trucks from the 2011 through 2015 model years, all equipped with dual fuel tanks.
comments powered by Disqus
Follow RTT